Jaime Stone
Family · Claremont, NHNPI 1417432303
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 308 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 19.5% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in NH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 308 payments — averaging $19.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- AbbVie$973
- Novo Nordisk$503
- Lilly USA, LLC$338
- Otsuka America Pharmaceutical, Inc.$266
- GSK$263
- plus $3K from 31 others
What the payments were for
- Food & beverage$6,101100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 61 | $1,190 |
| AbbVie | 51 | $973 |
| Novo Nordisk | 26 | $503 |
| Lilly USA, LLC | 21 | $338 |
| Otsuka America Pharmaceutical, Inc. | 14 | $266 |
| GSK | 16 | $263 |
| Amgen | 10 | $217 |
| Teva Pharmaceuticals USA, Inc. | 11 | $201 |
| Amarin Pharma, Inc. | 9 | $193 |
| Bayer | 8 | $177 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $174 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $155 |
| Regeneron Healthcare Solutions, Inc. | 6 | $149 |
| Novartis | 5 | $125 |
| Pfizer | 5 | $111 |
| Boehringer Ingelheim | 6 | $106 |
| Astellas Pharma US Inc | 5 | $101 |
| Biohaven Pharmaceuticals, Inc. | 5 | $95 |
| Merz North America, Inc. | 1 | $85 |
| Eisai Inc. | 4 | $77 |
| Exact Sciences | 3 | $69 |
| Alkermes, Inc. | 4 | $62 |
| Merck | 3 | $57 |
| Vanda Pharmaceuticals Inc. | 2 | $57 |
| Mylan Specialty L.p. | 1 | $46 |
| Baxter Healthcare | 1 | $43 |
| Johnson & Johnson | 1 | $43 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $38 |
| Abbott | 2 | $33 |
| Recordati_rare_diseases_inc. | 1 | $26 |
| Lundbeck LLC | 1 | $22 |
| Organon | 1 | $21 |
| Dexcom, Inc. | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $18 |
| Tandem Diabetes Care, Inc. | 1 | $16 |
| VBI Vaccine (delaware) Inc. | 1 | $15 |
How this compares
$6,101 in reported general payments places this provider in the 95th percentile of 713 family providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 27 | $41,087 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 55 | $37,880 |
| EliquisApixaban | 39 | $34,321 |
| FarxigaDapagliflozin Propanediol | 33 | $26,039 |
| MounjaroTirzepatide | 19 | $22,792 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 29 | $19,034 |
| BelbucaBuprenorphine Hcl | 11 | $9,743 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 17 | $8,400 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $4,789 |
| Lurasidone Hcl | 15 | $4,032 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 67 | $1,899 |
| Pregabalin | 28 | $1,195 |
| Atorvastatin Calcium | 108 | $1,161 |
| Bupropion XlBupropion Hcl | 24 | $1,150 |
| Omeprazole | 79 | $1,029 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere | $1,190 | $45,07462 claims |
| Novo NordiskOzempic | $503 | $41,08727 claims |
| GSKTrelegy Ellipta | $263 | $37,88055 claims |
| PfizerEliquis | $111 | $34,32139 claims |
| Lilly USA, LLCMounjaro | $338 | $22,79219 claims |
| Boehringer IngelheimStiolto Respimat | $106 | $8,40017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 713 family providers in New Hampshire.
Other family in Claremont
- Ashley PetrinClaremont$7K
- Carolyn FernandesClaremont$2K
- Tara Delle ChiaieHampton$548K
- Wendy WrightAmherst$447K
- Richard CareyNashua$51K
- Summer BellDerry$16K
- Laura HudsonDover$14K
- Debra KrisonNorth Hampton$13K
- Michelle WhiteBedford$9K
- Brant OliverConcord$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.